News

Philip Mease, MD, discusses BE BOLD, which delivers the first head-to-head superiority result for a joint-focused endpoint in psoriatic arthritis.

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

Novel CAR-T approaches targeting both CD19 and BCMA signal a paradigm shift in systemic sclerosis, alongside a growing focus on early diagnosis.

Anisha Dua, MD, MPH, discusses the largest US real-world cohort to date in GPA/MPA.

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.

Check out what coverage RheumLive has slated for the upcoming congress in London.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

Findings will be presented at the EULAR Annual Meeting and show significantly more bimekizumab-treated patients achieved the 16 week ACR50 primary endpoint.

New JIA guidance urges early biologics, favors oral methotrexate, adds mental health screening, and reshapes tapering and monitoring.

Phase 2/3 China trial shows IL‑17A antibody vunakizumab rapidly improves radiographic axSpA symptoms vs placebo, with benefits lasting to 32 weeks.

The new approval is backed by ADAPT SERON results showing significant MG-ADL improvement and consistent safety.

April is Sjögren's Awareness Month and we took a look at how the field's fast-growing pipeline is reshaping care.

The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

Experts discuss CTD-ILD guidance and nerandomilast reshape screening, progression monitoring, and multidisciplinary treatment.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Additional data from the BE BOLD trial supporting bimekizumab over risankizumab are slated for a future medical conference.

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

Take a look back at 5 RheumLive exclusive conversations ranging from PsA to giant cell arteritis from RWCS 2026 in Maui, Hawaii.

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

Dua discussed the vasculitis field's progression to "precision medicine" and more.

This preview of RWCS 2026 highlights some of the sessions and interviews to look forward to.

This rheumatology month in review emphasizes new data and FDA actions.